[CAS NO. 1092977-61-1] Evenamide
PRODUCTS SPECIFICATIONS [1092977-61-1]
DESCRIPTION [1092977-61-1]
Overview
| MDL | MFCD28502433 |
|---|---|
| Molecular Weight | 278.39 |
| Molecular Formula | C16H26N2O2 |
| SMILES | O=C(N(C)C)CNCCC1=CC=CC(OCCCC)=C1 |
Summary
Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker ( K i =0.4 µM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness [1] [2] .
IC50 & Target
Sodium channel [1]
In Vitro
Evenamide selectively blocks voltage-gated sodium channels (VGSCs) in a voltage-and use-dependent manner (K i =0.4 µM) and modulates sustained repetitive firing without inducing impairment of the normal neuronal excitability. Evenamide does not bind, inhibit or interact with over 130 receptors, enzymes, or transporters [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Evenamide is active in a wide range of psychiatric animal models in monotherapy and addon to antipsychotics. Evenamide is effective in attenuating the social interaction deficit in Cl 395 (PCP)-impaired rats (MED=1 mg/kg po) [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04461119 | Newron Pharmaceuticals SPA |
Schizophrenia
|
June 16, 2020 | Phase 2 |
| NCT03446274 | Newron Pharmaceuticals SPA |
Healthy
|
April 2, 2018 | Phase 1 |
Appearance
Liquid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Pure form | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 359.21 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.5921 mL | 17.9604 mL | 35.9208 mL |
| 5 mM | 0.7184 mL | 3.5921 mL | 7.1842 mL |
| 10 mM | 0.3592 mL | 1.7960 mL | 3.5921 mL |
References
- [1] Valentina Zuliani, et al. Advances in Design and Development of Sodium Channel Blockers. Ion Channels and Their Inhibitors pp 79-115.
- [2] Faravelli, et al. P.3.f.022 Evenamide (formerly NW-3509) targets new mechanisms, and represents a new approach to the management of untreated symptoms in schizophrenia.
Synonyms